ReviewCurrent radiology reports2018
BI-RADS 3: Current and Future Use of Probably Benign.
Review in Current radiology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- The underestimated risk of additional ipsilateral BI-RADS 3 lesions identified by preoperative ultrasound in breast cancer patients.Insights into imaging · 2026Article
- Optimising screening intervals and BI-RADS management pathways in ultrasound-based breast cancer screening: real-world evidence from Shenzhen (2018-2023).Breast cancer research and treatment · 2026Article
- Breast Cancer Screening Patterns Following National Crises: Experience from a Lebanese Tertiary Center.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Clinically Aware Learning: Ordinal Loss Improves Medical Image Classifiers.Journal of clinical medicine · 2026Article
- Cross-attention guided multi-modal network for breast ultrasound diagnosis incorporating objective clinical semantics.Frontiers in medicine · 2026Article
- Predicting radiological regression in benign breast hyperplasia: the prolactin-to-estradiol ratio as a prognostic biomarker.Frontiers in medicine · 2026Article
- Uncommon but Important: Tertiary Center Experience with Rare Cases of Breast Hamartoma.Life (Basel, Switzerland) · 2025Article
- Mammography-based artificial intelligence for breast cancer detection, diagnosis, and BI-RADS categorization using multi-view and multi-level convolutional neural networks.Insights into imaging · 2025Article
- Preoperative DBT-based radiomics for predicting axillary lymph node metastasis in breast cancer: a multi-center study.BMC medical imaging · 2025Article
- Value of deep learning model for predicting Breast Imaging Reporting and Data System 3 and 4A lesions on mammography.Quantitative imaging in medicine and surgery · 2025Article
- Evaluation of BI-RADS 3 Ultrasound Findings: the Frequency and Incidence of Malignant Lesions, and Tumor Size.Acta medica academica · 2025Article
- A Novel Phantom for Standardized Microcalcification Detection Developed Using a Crystalline Growth System.Tomography (Ann Arbor, Mich.) · 2025Article
- Screening of breast cancer in higher-risk Taiwanese women using contrast-enhanced mammography.Heliyon · 2025Article
- A Rare Case of Axillary Fibroadenoma in Accessory Breast Masquerading Malignancy.Indian journal of surgical oncology · 2024Article
- Follow-up results of BI-RADS 3 lesions on magnetic resonance imaging: a retrospective studyDiagnostic and interventional radiology (Ankara, Turkey) · 2024Article
- A Comprehensive Review of Breast Fibroadenoma: Correlating Clinical and Pathological Findings.Cureus · 2023Review
- Review
- Use of shear-wave elastography to distinguish complex and complicated fibroadenomas from simple fibroadenomas.Diagnostic and interventional radiology (Ankara, Turkey) · 2023Article
- Evaluation of Two-Year Follow-Up of Patients with BI-RADS 3 Breast Ultrasound Lesions in a Single Private Ultrasound Study.Advanced biomedical research · 2023Article
- Vacuum-assisted biopsy system for breast lesions: a potential therapeutic approach.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewProbably benign (BI-RADS 3) causes confusion for interpreting physicians and referring physicians and can induce significant patient anxiety. The best uses and evidence for using this assessment category in mammography, breast ultrasound, and breast MRI will be reviewed; the reader will have a better understanding of how and when to use BI-RADS 3. RECENT
findingsInterobserver variability in the use of BI-RADS 3 has been documented. The 5th edition of the BI-RADS atlas details the appropriate use of BI-RADS 3 for diagnostic mammography, ultrasound, and MRI, and discourages its use in screening mammography. Data mining, elastography, and diffusion weighted MRI have been evaluated to maximize the accuracy of BI-RADS 3. SUMMARY: BI-RADS 3 is an evolving assessment category. When used properly, it reduces the number of benign biopsies while allowing the breast imager to maintain a high sensitivity for the detection of early stage breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.